Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Oct 19, 2010

Premium

Ivan Trifunovich has become president and CEO of Helicos BioSciences, effective Oct. 14 (see story, this issue). He replaces Ron Lowy, who will continue to be a company director.

Prior to becoming CEO, Trifunovich was a senior consultant to Helicos' board of directors and was elected as executive chairman of the board on Sept. 15. Previously, he was a strategic consultant to global companies in the life sciences industry, and before that, senior vice president of Third Wave Technologies. Prior to that, he held sales and marketing as well as R&D positions at several large pharmaceutical companies.

According to documents filed with the Securities and Exchange Commission, Trifunovich will receive a salary of $30,000 per month, subject to a potential annual increase by the compensation committee of the company’s board of directors; a bonus opportunity of up to 30 percent of his annual base salary; and an equity award of restricted stock equal to 5 percent of the company’s fully diluted capital stock.

He holds a PhD in organic chemistry from the University of California, Los Angeles, and an MBA from the University of Pennsylvania's Wharton School of Business.


Paris-based strategic consulting firm Bionest Partners has appointed Sean Xinghua Hu as managing director for North America and head of Bionest USA.

Previously, Hu was a consultant at IMS Management consulting/SDG Life Sciences and AT Kearney. He was also an early participant in the Human Genome Project and later involved in the International HapMap Project. He also held positions in business development at Illumina, in sales and marketing at Bristol-Myers Squibb, and in R&D and operations at CuraGen.

Hu holds a PhD in genomics from New York University, an MBA from the Wharton School of Business at the University of Pennsylvania, and a BS in chemistry from Peking University.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.